|By PR Newswire||
|April 7, 2014 07:00 AM EDT||
SEATTLE, April 7, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference in New York later this week. The presentation is scheduled for Wednesday, April 9, 2014 at 3:00 p.m. EDT.
The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, Omidria™ (OMS302) for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with US commercial launch planned for the second half of 2014. Omeros' six other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.
SOURCE Omeros Corporation
Feb. 19, 2017 08:00 PM EST Reads: 2,662
Feb. 19, 2017 06:45 PM EST Reads: 2,993
Feb. 19, 2017 06:15 PM EST Reads: 936
Feb. 19, 2017 06:00 PM EST Reads: 1,246
Feb. 19, 2017 05:45 PM EST Reads: 5,212
Feb. 19, 2017 05:45 PM EST Reads: 787
Feb. 19, 2017 05:00 PM EST Reads: 7,895
Feb. 19, 2017 05:00 PM EST Reads: 772
Feb. 19, 2017 05:00 PM EST Reads: 8,002
Feb. 19, 2017 05:00 PM EST Reads: 1,462
Feb. 19, 2017 04:15 PM EST Reads: 1,938
Feb. 19, 2017 03:45 PM EST Reads: 1,267
Feb. 19, 2017 02:45 PM EST Reads: 909
Feb. 19, 2017 02:30 PM EST Reads: 2,096
Feb. 19, 2017 02:30 PM EST Reads: 1,064